July news: Developing novel reimbursement practices

Cell and gene therapies are different to traditional medicines and existing reimbursement practices do not easily accommodate the possible outstanding value that these potentially curative and disease-modifying therapies could deliver.

The Health Economics and Market Access Team at CGT Catapult have been looking at how outcomes-based reimbursement could support the adoption of these therapies. Outcomes-based reimbursement requires patient outcomes data to be collected, analysed and linked to payments; central to this is the availability of a suitable data collection and management infrastructure. 

In a series of case studies, the team describes opportunities and challenges with current data collection infrastructure and identifies approaches for its optimisation:
 


Additionally, this recent paper published in the Journal of Market Access & Health Policy identifies the key requirements for upgrading the Systemic Anti-Cancer Therapy (SACT) database and European Society for Blood and Marrow Transplantation (EBMT) registry for the purposes of enabling outcomes-based reimbursement in oncology.

Discover who we are